Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Free Cash Flow for 3 consecutive years, with -$41.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 9.31% to -$41.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.0 million through Dec 2025, up 7.04% year-over-year, with the annual reading at -$148.0 million for FY2025, 7.04% up from the prior year.
  • Free Cash Flow hit -$41.0 million in Q4 2025 for NewAmsterdam Pharma, down from -$32.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$12.6 million in Q3 2024 to a low of -$55.0 million in Q1 2024.
  • Historically, Free Cash Flow has averaged -$37.4 million across 3 years, with a median of -$37.0 million in 2024.
  • Biggest five-year swings in Free Cash Flow: soared 73.23% in 2024 and later tumbled 160.88% in 2025.
  • Year by year, Free Cash Flow stood at -$33.1 million in 2023, then dropped by 13.32% to -$37.5 million in 2024, then decreased by 9.31% to -$41.0 million in 2025.
  • Business Quant data shows Free Cash Flow for NAMS at -$41.0 million in Q4 2025, -$32.8 million in Q3 2025, and -$37.8 million in Q2 2025.